Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
Operator of a biotechnology company intended to provide novel small molecule medicines targeting g-protein-coupled receptors. The company provides industrial-scale drug discovery using novel screening technologies and structure-based drug design, enabling medical researchers to easily find patients' treatments for a wide range of diseases.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.
Bright Peak Therapeutics
Series B in 2021
Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of innovative treatments for serious and orphan diseases. The company focuses on soluble guanylate cyclase (sGC) pharmacology to harness the therapeutic potential of next-generation sGC stimulators. Its key product candidates include Olinciguat, which is undergoing Phase II studies for sickle cell disease, and Praliciguat, currently in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction. Additionally, Cyclerion is developing IW-6463, an orally administered central nervous system-penetrant sGC stimulator in Phase I trials aimed at treating neurodegenerative diseases. The company is also exploring liver-targeted and lung-targeted sGC stimulators to expand its therapeutic offerings. Cyclerion Therapeutics was incorporated in 2018 and is dedicated to addressing unmet medical needs through its innovative pipeline.
Engine Biosciences Pte. Ltd. is a biotechnology company that specializes in drug discovery by leveraging machine learning and genomics. Founded in 2014 and based in Singapore, the company has developed a validated platform that integrates high-throughput wet lab experimentation with artificial intelligence algorithms. This unique approach enables the mapping and analysis of complex biological networks and gene interactions, facilitating the identification of disease-driving errors. The platform supports researchers and drug developers in various aspects of drug discovery, including target discovery, drug repositioning, and pathway analysis. Engine Biosciences collaborates with American Fortune 500 companies and research institutions, aiming to accelerate and reduce the costs associated with the research and development process for new medical therapies. The company’s leadership team includes experts from renowned institutions such as MIT, Harvard, Mayo Clinic, and UCSD.
Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.
Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.
Faze Medicines is a biotechnology company established in 2020 and based in Cambridge, Massachusetts. The company focuses on developing small molecule drugs targeting the underlying drivers of disease pathology, particularly for conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines leverages innovative research on biomolecular condensates to create potential therapeutic breakthroughs. Through advanced screening and proteomics techniques, the company aims to pioneer new treatments for various diseases, including frontotemporal dementia (FTD) and DM1, thereby addressing significant unmet medical needs.
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Private Equity Round in 2020
Ambrx is a biopharmaceutical company headquartered in La Jolla, California, that specializes in developing engineered precision biologics using a proprietary technology platform to incorporate synthetic amino acids into proteins. The company focuses on creating protein therapeutics that enhance potency, reduce dosing frequency, and improve drug homogeneity. Its development pipeline includes antibody drug conjugates (ADCs), bi-specific product candidates, and long-acting protein therapeutics, alongside various early-stage programs. Ambrx has established collaborations with MabSpace Biosciences for ADC development in oncology, BeiGene for the commercialization of biologic drugs, and NovoCodex Biopharmaceuticals for the advancement of ARX305, an ADC targeting CD70 positive cancers. Founded in 2003, the company aims to innovate and expand the capabilities of biologic therapies.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
Autobahn Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing small molecule therapies for central nervous system (CNS) disorders. The company focuses on leveraging its expertise in brain-targeting chemistry to create innovative treatments that harness the regenerative capabilities of the human body. Its primary product candidate, ABX-002, is a thyroid hormone receptor beta agonist aimed at treating multiple sclerosis and adrenomyeloneuropathy, a rare genetic disorder. Founded in 2017, Autobahn Therapeutics is committed to addressing significant unmet medical needs in areas such as neuropsychiatry, neurodegeneration, and neuroinflammation, utilizing validated clinical and biological targets to guide its research and development efforts.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.
Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.
Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, that specializes in the discovery, development, and commercialization of innovative therapies for ocular surface diseases. Founded in 2015, the company is primarily focused on its lead product candidate, OC-01, a nicotinic acetylcholine receptor agonist currently undergoing Phase III clinical trials for the treatment of dry eye disease. This condition, which affects over 30 million Americans, is characterized by a chronic lack of sufficient tears, leading to discomfort and potential vision problems. OC-01 is developed as a nasal spray and aims to restore tear film homeostasis by activating the trigeminal parasympathetic pathway, thereby stimulating natural tear production. Additionally, the company is exploring the use of OC-01 for neurotrophic keratitis, further expanding its therapeutic potential in ocular health.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Kaleido Biosciences is a clinical-stage healthcare company based in Lexington, Massachusetts, dedicated to developing microbiome metabolic therapies (MMTs) aimed at treating various diseases and improving human health. Founded in 2015, the company is advancing a diverse pipeline of MMT candidates targeting conditions such as urea cycle disorders, hepatic encephalopathy, multi-drug resistant infections, cardiometabolic and liver diseases, and immune oncology. Kaleido employs a unique, chemistry-driven approach to harness the microbiome's potential, focusing on modulating its metabolic output and profile by influencing the existing microbial functions. The company has established collaborations with notable institutions, including Gustave Roussy Cancer Center and Washington University School of Medicine, to further explore the applications of MMTs in immuno-oncology and other health conditions.
Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.
PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
PatientsLikeMe, Inc. operates a healthcare data-sharing platform that allows patients to share their symptoms, treatments, and health experiences with a broad audience, including caregivers, researchers, and pharmaceutical companies. This platform aims to enhance the understanding of various health conditions, such as cancer, mental health issues, and chronic diseases, ultimately contributing to the development of new treatments. With over 600,000 members, PatientsLikeMe serves as a trusted source for real-world disease information and has published more than 100 research studies, demonstrating its commitment to integrating patient voices into research and public policy. The company collaborates with major pharmaceutical firms and government organizations to advance health management and outcomes. Founded in 2004 and based in Cambridge, Massachusetts, PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.
Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing pharmaceutical products aimed at treating various human diseases, including those related to immunology, metabolism, cardiology, and ophthalmology. The company's pipeline features several drug candidates, such as LX1031, which has completed Phase II trials for irritable bowel syndrome; LX4211, also in Phase II trials for type 2 diabetes; LX2931, currently undergoing Phase II trials for rheumatoid arthritis; and LX1032, which has completed Phase II trials for carcinoid syndrome symptoms. Additionally, the company is developing LX7101 for glaucoma in preclinical stages and is working on LX9211 for neuropathic pain, along with sotagliflozin for heart failure and type 1 diabetes. Lexicon has formed strategic alliances and collaborations with various pharmaceutical companies and research organizations to enhance its drug discovery and development capabilities.
PatientsLikeMe, Inc. operates a healthcare data-sharing platform that allows patients to share their symptoms, treatments, and health experiences with a broad audience, including caregivers, researchers, and pharmaceutical companies. This platform aims to enhance the understanding of various health conditions, such as cancer, mental health issues, and chronic diseases, ultimately contributing to the development of new treatments. With over 600,000 members, PatientsLikeMe serves as a trusted source for real-world disease information and has published more than 100 research studies, demonstrating its commitment to integrating patient voices into research and public policy. The company collaborates with major pharmaceutical firms and government organizations to advance health management and outcomes. Founded in 2004 and based in Cambridge, Massachusetts, PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals. The company's next-generation drug-eluting stent systems are designed to optimize localized drug delivery to provide a safe and effective treatment for cardiovascular patients.
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.